Clinical Trials Logo

B-cell Lymphoid Malignancies clinical trials

View clinical trials related to B-cell Lymphoid Malignancies.

Filter by:
  • None
  • Page 1

NCT ID: NCT05822843 Recruiting - Clinical trials for B-cell Lymphoid Malignancies

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

Start date: August 2, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK (pharmacokinetics), and preliminary efficacy and to establish the MTD (maximum tolerated dose), if any, and RP2D (recommended phaseII dose) of ESG206 in adult subjects with B lymphoid malignancies.

NCT ID: NCT05263739 Not yet recruiting - Clinical trials for B-cell Lymphoid Malignancies

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

Start date: June 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK, and preliminary efficacy and to establish the MTD, if any, and RP2D(s) of ESG206 in adult subjects with B lymphoid malignancies.

NCT ID: NCT04684979 Withdrawn - Clinical trials for Non-Hodgkin Lymphoma

Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies

Start date: March 28, 2022
Phase: Phase 2
Study type: Interventional

This research study is being conducted to treat patients with B-cell lymphoid malignancies. These types of cancers include diffuse large cell (DLBCL) non-Hodgkin's lymphoma (NHL), mantle cell NHL, any indolent B cell NHL (such as follicular, small cell or marginal zone NHL), or chronic lymphocytic leukemia (CLL). Patients with these types of lymphomas have been shown to benefit from peripheral blood stem cell transplantation (PBSCT). PBSCT uses healthy blood stem cells from a donor to replace your diseased or damaged bone marrow. Before undergoing PBSCT, you'll receive chemotherapy and/or radiation to destroy your diseased cells and prepare your body for the donor cells. This is called a "conditioning regimen." Non-myeloablative (NMA) conditioning causes minimal cell death. This research study will look at a course of treatment using NMA conditioning regimen including low dose chemotherapy and low dose radiation as well as rituximab and PBSCT from a compatible donor. The primary aim is to obtain a preliminary estimate of the overall and event-free survival 1 year post-transplant after NMA.

NCT ID: NCT02569476 Completed - Clinical trials for B-cell Lymphoid Malignancies

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Start date: January 13, 2016
Phase: Phase 1
Study type: Interventional

This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.